Director purchase disclosed
Eric Sachetta, a director at Sensus Healthcare, Inc. (NASDAQ: SRTS), purchased 2,000 shares of the companys common stock in a single transaction on February 24, 2026. The shares were acquired at $3.81 apiece, for a total outlay of $7,620, according to a Form 4 filing with the Securities and Exchange Commission. After the purchase, Sachetta directly holds 142,113 shares of Sensus Healthcare.
Share price context
The purchase occurred as Sensus stock traded near $3.92. The share price is down about 18 percent over the past 12 months. InvestingPro analysis cited in company coverage characterizes SRTS as appearing undervalued at current levels, with analyst price targets in a range between $6 and $8. An InvestingPro tip also highlights that the company reportedly holds more cash than debt, which is noted as supportive of financial flexibility. For subscribers, additional ProTips and a full Pro Research Report are available for SRTS and more than 1,400 other U.S. equities.
Recent financial performance
Sensus Healthcare reported fourth-quarter 2025 results that fell short of expectations. The company posted earnings per share of -$0.19, missing the forecasted -$0.04. Revenue for the quarter was $4.9 million, significantly below the anticipated $8.88 million. These shortfalls have been a focus for investors evaluating Sensuss near-term financial position.
Product and financing initiatives
Alongside its financial disclosure, Sensus Healthcare has introduced Sensus Link, a cloud-based software solution designed for its SRT-100 superficial radiotherapy systems. The company describes this offering as an add-on available to both new and existing customers, intended to enhance workflow and treatment documentation. Separately, Sensus launched Sensus Healthcare Financial Services, a program to simplify acquisition of its radiotherapy systems by offering flexible purchasing or leasing options aimed at dermatology practices.
What this means
The director purchase and the companys new commercial initiatives arrive against a backdrop of a quarterly earnings and revenue shortfall and recent share-price weakness. The reported cash position relative to debt, as noted in InvestingPro commentary, is presented as a factor supporting Sensuss financial flexibility, while product and financing rollouts aim to broaden the companys customer value proposition.